LPCAT3 and metabolic dysfunction-associated steatohepatitis: This led to a decrease in hepatic steatosis and inflammation, indicating that KP improves ERS by lowering the expression levels of LXRα and LPCAT3, thereby exhibiting a potential therapeutic effect on NASH (Xiang et al., 2021).